Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Biotech companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field., part of AstraZeneca. FDA records under its name, each linked to the record. See the AstraZeneca group view.
As of Nov 22, 2026, FDA's public records list MedImmune Oncology with 1 drug application. The most recent is a drug application dated Dec 17, 1993: Neutrexin.
Drug applications: 1
Latest records
Newest first across sources; each opens the record
HexalenTreatment of advanced adenocarcinoma of the ovary. · Feb 9, 1984 · approved Dec 26, 1990
Names and identifiers
Appears as
MEDIMMUNE ONCOLOGY
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.